Pernod Ricard SA (0HAT)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 66.53 |
|---|---|
| 52-week range | 57.88 – 88.58 |
| Return, 1 month / 3 months | +12.3% / +4.7% |
| Return, 1 year / 3 years | −18.0% / −53.2% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 27.6% |
| Worst drawdown (1 year) | -29.4% |
| Average daily value traded | 8.23M EUR |
| Dividend yield | 7.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pernod Ricard is a French drinks company based in Paris that makes and markets spirits and wines. Its range covers whisky, vodka, cognac, anise-flavoured spirits, gin, rum and champagne, with brands such as Absolut, Jameson, Chivas Regal, Martell, Ricard, Mumm and Perrier-Jouët. The company serves drinkers through retailers, bars, restaurants and distributors in markets around the world, and it also runs brand-building and responsible-drinking programmes alongside its production and distribution work.
The shares are listed on the London Stock Exchange in UK under the code 0HAT, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pernod Ricard SA (0HAT) trades on the London Stock Exchange in UK. It last closed at EUR 66.53 on 27 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 1,618 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.0% and over the last three months it rose 4.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 42 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 1.5% | ||
| From 52-week high | -23.7% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 4.7% | ||
| 6-month return | 5.7% | ||
| 12-month return, skipping the last month | -27.0% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.4% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 8.23M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 87 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.1% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | +12.3% |
| 3 months | +4.7% |
| 6 months | +5.7% |
| 1 year | −18.0% |
| 3 years | −53.2% |
| 5 years | −59.7% |
Signals
| 50-day / 200-day average | 63.06 / 65.53 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.34 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Jul 2026 | EUR 2.3500 |
| 24 Nov 2025 | EUR 2.3500 |
| 23 Jul 2025 | EUR 2.3500 |
| 25 Nov 2024 | EUR 2.3500 |
| 17 Jul 2024 | EUR 2.3500 |
| 24 Nov 2023 | EUR 2.6400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.